The board of directors of Sino Biopharmaceutical Limited announced that the oncology medicine "Bortezomib for Injection" (specifications: 1.0mg and 3.5mg) of the Group has obtained the notice of approval of supplemental applications issued by the National Medical Products Administration of the People's Republic of China, and has passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs (the Consistency Evaluation). Bortezomib is a proteasome inhibitor with anti-tumor effects in targeted therapy, which is applicable to the treatment of Multiple Myeloma (MM) and Mantle Cell Lymphoma (MCL). Bortezomib is a fundamental drug for the treatment of myeloma. Combination therapy based on Bortezomib has an unshakable position in the first-line treatment of myeloma, especially for high-risk patients and those with renal insufficiency. Bortezomib, which is suitable for various patient groups and treatment stages of MM, has a notable efficacy in enhancing the survival rate of myeloma patients. Currently, the access of domestic patients to imported branded Bortezomib has been limited to a certain extent due to its high price. Having passed the Consistency Evaluation, the Qianping of the Group is recognized as an alternative for the imported drug. It can provide clinicians another important option for the treatment of myeloma and MCL, and greatly reduce the treatment costs for patients.